) and partner,
), presented positive phase III data on their experimental
psoriasis treatment, brodalumab. The candidate was evaluated in a
phase III study, AMAGINE-1, in patients with moderate-to-severe
Amgen and AstraZeneca said that the primary as well as secondary
endpoints were achieved. Two doses of brodalumab (140 mg and 210
mg) were compared to placebo. While 83.3% of patients in the 210 mg
group and 60.3% of patients in the 140 mg group achieved PASI 75
responses, only 2.7% of patients in the placebo arm achieved the
As far as PASI 90 response was concerned, 70.3% and 42.5% of
patients in the 210 mg and 140 mg arms, respectively, achieved the
same compared to 0.9% in the placebo arm. PASI 100 responses were
achieved by 41.9% and 23.3% patients in the 210 mg and 140 mg arms,
respectively, compared to just 0.5% in the placebo arm.
The PASI score basically measures psoriatic plaque redness,
scaling and thickness and the extent of involvement in each region
of the body.
The phase III data on brodalumab is encouraging for both Amgen
and AstraZeneca. These results bring Amgen and AstraZeneca a step
closer to regulatory filing though two more phase III studies are
still ongoing - AMAGINE-2 and AMAGINE-3. Results from these two
head-to-head studies comparing brodalumab to Stelara (ustekinumab)
should be out later this year. Both companies are working on
strengthening their product portfolio and brodalumab is one of the
key candidates in their pipeline. According to a recent press
release issued by AstraZeneca, analyst estimates for brodalumab
range between $0.5 billion - $1.5 billion.
However, the psoriasis market is highly crowded with treatments
like Stelara and Otezla among others. Moreover, several companies
have late-stage candidates in development for the psoriasis
Amgen and AstraZeneca are both Zacks Rank #3 (Hold) stocks. Some
better-ranked stocks in the health care sector include
). While Gilead is a Zacks Rank #1 (Strong Buy) stock, Allergan is
a Zacks Rank #2 (Buy) stock.
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
ALLERGAN INC (AGN): Free Stock Analysis Report
AMGEN INC (AMGN): Free Stock Analysis Report
ASTRAZENECA PLC (AZN): Free Stock Analysis
GILEAD SCIENCES (GILD): Free Stock Analysis
To read this article on Zacks.com click here.